Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

This post was originally published on this site

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating) was the target of unusually large options trading on Wednesday. Stock investors purchased 1,002 put options on the company. This is an increase of 1,791% compared to the typical volume of 53 put options.

Large investors have recently modified their holdings of the company. Select Equity Group L.P. lifted its stake in shares of Maravai LifeSciences by 69.5% in the fourth quarter. Select Equity Group L.P. now owns 20,542,503 shares of the company’s stock valued at $860,731,000 after buying an additional 8,420,492 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Maravai LifeSciences by 12.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 8,965,103 shares of the company’s stock worth $316,198,000 after purchasing an additional 962,082 shares during the period. BlackRock Inc. lifted its stake in Maravai LifeSciences by 30.7% during the fourth quarter. BlackRock Inc. now owns 6,053,047 shares of the company’s stock worth $253,622,000 after purchasing an additional 1,420,288 shares during the period. UBS Asset Management Americas Inc. lifted its stake in Maravai LifeSciences by 16.8% during the third quarter. UBS Asset Management Americas Inc. now owns 4,133,186 shares of the company’s stock worth $202,857,000 after purchasing an additional 594,447 shares during the period. Finally, Champlain Investment Partners LLC lifted its stake in Maravai LifeSciences by 0.8% during the first quarter. Champlain Investment Partners LLC now owns 3,582,530 shares of the company’s stock worth $126,356,000 after purchasing an additional 28,405 shares during the period. 50.18% of the stock is currently owned by institutional investors.

NASDAQ MRVI opened at $31.53 on Thursday. Maravai LifeSciences has a 1-year low of $23.16 and a 1-year high of $63.55. The company has a current ratio of 7.14, a quick ratio of 6.55 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $8.05 billion, a PE ratio of 19.83 and a beta of 0.76. The firm’s fifty day simple moving average is $33.58 and its 200-day simple moving average is $35.17.

Maravai LifeSciences (NASDAQ:MRVIGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. The business had revenue of $244.30 million for the quarter, compared to the consensus estimate of $232.29 million. Maravai LifeSciences had a net margin of 25.25% and a return on equity of 96.51%. Maravai LifeSciences’s revenue for the quarter was up 64.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 earnings per share. As a group, analysts predict that Maravai LifeSciences will post 1.85 EPS for the current year.

A number of equities analysts have issued reports on the company. Robert W. Baird decreased their price target on Maravai LifeSciences from $48.00 to $40.00 in a research note on Friday, May 6th. Morgan Stanley cut their price objective on Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating for the company in a research report on Friday, February 25th. Finally, Zacks Investment Research downgraded Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Maravai LifeSciences currently has a consensus rating of “Buy” and a consensus target price of $48.40.

Maravai LifeSciences Company Profile (Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Featured Articles

Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.